^
    2d
    Single-cell profiling of HDAC inhibitor-induced EBV lytic heterogeneity defines abortive and refractory states in B lymphoblasts. (PubMed, PLoS Pathog)
    We therefore characterized the impact of pan-HDAC inhibitor, panobinostat, and class I HDAC inhibitor, nanatinostat, on the growth, survival, and lytic reactivation of four EBV-positive cell lines: P3HR1-ZHT BL, Jijoye BL, IBL-1 immunoblastic lymphoma, and de novo infection derived lymphoblastoid cell lines (LCL). Functional validation through a Cas9-RNP approach revealed that the CD137 receptor is indeed involved in preventing successful lytic reactivation. These data have important implications for how we approach oncolytic therapies for EBV-associated malignancies.
    Journal • IO biomarker
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Farydak (panobinostat) • nanatinostat (VRx-3996)
    4ms
    Single-Cell Profiling of HDAC Inhibitor-Induced EBV Lytic Heterogeneity Defines Abortive and Refractory States in B Lymphoblasts. (PubMed, bioRxiv)
    We therefore characterized the impact of pan-HDAC inhibitor, panobinostat, and class I HDAC inhibitor, nanatinostat, on the growth, survival, and lytic reactivation of four EBV-positive cell lines: P3HR1-ZHT BL, Jijoye BL, IBL-1 immunoblastic lymphoma, and de novo infection derived lymphoblastoid cell lines (LCL). Single-cell RNA sequencing provided evidence of upregulated immune signaling pathways in this abortive lytic population. This study provides in depth characterization of lytic reactivation with a biologically relevant stimulus.
    Journal • IO biomarker
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Farydak (panobinostat) • nanatinostat (VRx-3996)
    1year
    NAVAL-1: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (clinicaltrials.gov)
    P2, N=102, Terminated, Viracta Therapeutics, Inc. | Trial completion date: Dec 2026 --> Jan 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Dec 2024; Sponsor Decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    1year
    A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=8, Terminated, Viracta Therapeutics, Inc. | N=14 --> 8 | Trial completion date: Oct 2025 --> Jan 2025 | Recruiting --> Terminated; Sponsor Decision
    Enrollment change • Trial completion date • Trial termination
    |
    Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    1year
    VT3996-301: Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC (clinicaltrials.gov)
    P1, N=26, Terminated, Viracta Therapeutics, Inc. | Phase classification: P1/2 --> P1 | Trial completion date: Oct 2025 --> Jan 2025 | Active, not recruiting --> Terminated; Sponsor Decision
    Phase classification • Trial completion date • Trial termination
    |
    Keytruda (pembrolizumab) • Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    1year
    NAVAL-1: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (clinicaltrials.gov)
    P2, N=140, Active, not recruiting, Viracta Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    over1year
    VT3996-301: Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC (clinicaltrials.gov)
    P1/2, N=26, Active, not recruiting, Viracta Therapeutics, Inc. | N=130 --> 26
    Enrollment change • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    over1year
    VT3996-301: Nanatinostat Plus Valganciclovir in Patients with Advanced EBV+ Solid Tumors, and in Combination with Pembrolizumab in EBV+ RM-NPC (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Viracta Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    2years
    A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=14, Recruiting, Viracta Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    2years
    A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Viracta Therapeutics, Inc.
    New P1 trial • Metastases
    |
    Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    2years
    VT3996-201: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=64, Completed, Viracta Therapeutics, Inc. | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    Valcyte (valganciclovir) • nanatinostat (VRx-3996)
    2years
    NAVAL-1: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (clinicaltrials.gov)
    P2, N=140, Recruiting, Viracta Therapeutics, Inc.
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Valcyte (valganciclovir) • nanatinostat (VRx-3996)